DAX24.953 -0,1%Est506.042 -0,1%MSCI World4.343 -0,1%Top 10 Crypto8,5500 -2,6%Nas23.102 -0,6%Bitcoin56.804 -1,8%Euro1,1861 -0,3%Öl70,23 +1,7%Gold5.056 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens Energy ENER6Y SAP 716460 Rheinmetall 703000 BASF BASF11 Gerresheimer A0LD6E Lufthansa 823212 NVIDIA 918422 Microsoft 870747 Amazon 906866 Deutsche Telekom 555750 Commerzbank CBK100 DroneShield A2DMAA Allianz 840400 Novo Nordisk A3EU6F Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas tiefer -- Lufthansa: Streiks am Donnerstag -- Siemens Energy: Rekordaufträge -- Commerzbank hebt Ziele an -- BMW, Telekom, Goldpreis, Lyft, Moderna, Robinhood, VERBIO im Fokus
Top News
Ausblick: Siemens veröffentlicht Zahlen zum vergangenen Quartal Ausblick: Siemens veröffentlicht Zahlen zum vergangenen Quartal
Zahlen von T-Mobile US schicken Deutsche Telekom-Aktie nach unten Zahlen von T-Mobile US schicken Deutsche Telekom-Aktie nach unten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
97,29 EUR -5,01 EUR -4,90 %
STU
88,91 CHF -4,04 CHF -4,34 %
BRX
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.52,19 Mrd. EUR

KGV25,01Div. Rendite1,89%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireJapan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b...
PR NewswireCSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
PR NewswireCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
PR NewswireCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
PR NewswireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
PR NewswireHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
PR NewswireSwissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B
PR NewswireCSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
PR NewswireCSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...
PR NewswireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireCSL and uniQure Win 2023 Prix Galien USA Award

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.